JRoon71
1 minute ago
why are they waiting to chop the roughly $20m in R&D spend?
Don't forget, most of that is salaries of existing employees (Ketchum and his staff, etc.), milestone payments to Mochida, Vascepa supply that they provide to various entities for 3rd party trials, the cost of applying for an